Literature DB >> 7298856

Suppression of atherogenesis in cholesterol-fed rabbit treated with nifedipine.

P D Henry, K I Bentley.   

Abstract

We tested the effects of nifedipine, a calcium antagonist, on atherogenesis in rabbits fed a 2% cholesterol diet. The drug was given orally, 40 mg/dl, and control rabbits received placebo. Nifedipine was well tolerated, and evoked only transient, moderate reductions in arterial pressure. Plasma total cholesterol after 8 wk before killing the rabbits was similar in the placebo and nifedipine-treated groups, averaging 1,903 +/- 138 (n = 13) and 1,848 +/- 121 mg/dl (n = 13; mean +/- SE; P greater than 0.8). In placebo-treated rabbits, aortic lesions stainable with Sudan IV covered 40 +/- 5% of the intimal surface, and the cholesterol concentration in aortic tissue was 47 +/- 5 mg/g protein. Corresponding values for the aortas from nifedipine-treated rabbits were significantly lower and averaged 17 +/- 3% (P less than 0.001) and 29 +/- 2 mg/g protein (P less than 0.001). We conclude that nifedipine suppressed atherogenesis without reducing hypercholesterolemia.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7298856      PMCID: PMC370933          DOI: 10.1172/jci110384

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  23 in total

1.  Technics for studying atherosclerotic lesions.

Authors:  R L HOLMAN; H C McGILL; J P STRONG; J C GEER
Journal:  Lab Invest       Date:  1958 Jan-Feb       Impact factor: 5.662

2.  Plaque reversal with MgEDTA in experimental atherosclerosis: elastin and collagen metabolism.

Authors:  A Wartman; T L Lampe; D S McCann; A J Boyle
Journal:  J Atheroscler Res       Date:  1967 May-Jun

3.  alpha-Adrenergic blockade and inhibition of A23187 mediated Ca2+ uptake by the calcium antagonist verapamil in rat liver cells.

Authors:  P F Blackmore; M F El-Refai; J H Exton
Journal:  Mol Pharmacol       Date:  1979-05       Impact factor: 4.436

4.  Effects of anticalcifying and antifibrobrotic drugs on pre-established atherosclerosis in the rabbit.

Authors:  W Hollander; J Paddock; S Nagraj; M Colombo; B Kirkpatrick
Journal:  Atherosclerosis       Date:  1979-05       Impact factor: 5.162

5.  The effect of disodium ethane-1-hydroxy-1,1-diphosphonate (EHDP) on a rabbit model of athero-arteriosclerosis.

Authors:  I Y Rosenblum; L Flora; R Eisenstein
Journal:  Atherosclerosis       Date:  1975 Nov-Dec       Impact factor: 5.162

6.  Suppression of calcific fibrous-fatty plaque formation in rabbits by agents not affecting elevated serum cholesterol levels. The effect of thiophene compounds.

Authors:  C T Chan; H Wells; D M Kramsch
Journal:  Circ Res       Date:  1978-07       Impact factor: 17.367

7.  The use of A23187 to demonstrate the role of intracellular calcium in causing ultrastructural damage in mammalian muscle.

Authors:  S J Publicover; C J Duncan; J L Smith
Journal:  J Neuropathol Exp Neurol       Date:  1978-09       Impact factor: 3.685

Review 8.  Comparative pharmacology of calcium antagonists: nifedipine, verapamil and diltiazem.

Authors:  P D Henry
Journal:  Am J Cardiol       Date:  1980-12-01       Impact factor: 2.778

9.  Calcium dependence of toxic cell death: a final common pathway.

Authors:  F A Schanne; A B Kane; E E Young; J L Farber
Journal:  Science       Date:  1979-11-09       Impact factor: 47.728

10.  The inhibitory effect of new diphosphonic acids on aortic and kidney calcification in vivo.

Authors:  M Potokar; M Schmidt-Dunker
Journal:  Atherosclerosis       Date:  1978-08       Impact factor: 5.162

View more
  53 in total

Review 1.  Antiatherogenic effects of calcium-channel blockers: possible mechanisms of action.

Authors:  P D Henry
Journal:  Cardiovasc Drugs Ther       Date:  1990-08       Impact factor: 3.727

Review 2.  Atherosclerosis: inhibition of regression as therapeutic possibilities.

Authors:  M J Davies; D M Krikler; D Katz
Journal:  Br Heart J       Date:  1991-06

3.  Quantitative analysis of antiatherosclerotic effect of nifedipine in cholesterol-fed rabbits.

Authors:  Y Ohta; N Higuchi; S Emura; T Takashima; K Oogushi; H Kato; K Ohmori; T Sunaga
Journal:  Cardiovasc Drugs Ther       Date:  1990-08       Impact factor: 3.727

4.  Retardation of coronary artery disease in humans by the calcium-channel blocker nifedipine: results of the INTACT study (International Nifedipine Trial on Antiatherosclerotic Therapy).

Authors:  P R Lichtlen; P G Hugenholtz; W Rafflenbeul; H Hecker; S Jost; P Nikutta; J W Deckers
Journal:  Cardiovasc Drugs Ther       Date:  1990-08       Impact factor: 3.727

Review 5.  Influence of nifedipine on experimental arteriosclerosis.

Authors:  A M Knorr; S Kazda
Journal:  Cardiovasc Drugs Ther       Date:  1990-08       Impact factor: 3.727

6.  Effect of nifedipine administration on pulse wave velocity (PWV) of chronic hemodialysis patients--2-year trial.

Authors:  Y Saito; K Shirai; J Uchino; M Okazawa; Y Hattori; T Yoshida; S Yoshida
Journal:  Cardiovasc Drugs Ther       Date:  1990-08       Impact factor: 3.727

7.  Retardation of development and progression of coronary atherosclerosis: a new indication for calcium antagonists?

Authors:  W Schneider; G Kober; P Roebruck; H Noack; M Alle; G Cieslinski; N Reifart; M Kaltenbach
Journal:  Eur J Clin Pharmacol       Date:  1990       Impact factor: 2.953

Review 8.  Cell culture systems to study progression and inhibition of intimal proliferations.

Authors:  E Betz
Journal:  Basic Res Cardiol       Date:  1991 Mar-Apr       Impact factor: 17.165

9.  Long term effects of nisoldipine on the progression of coronary atherosclerosis and the occurrence of clinical events: the NICOLE study.

Authors:  J A Dens; W J Desmet; P Coussement; I K De Scheerder; K Kostopoulos; P Kerdsinchai; C Supanantaroek; J H Piessens
Journal:  Heart       Date:  2003-08       Impact factor: 5.994

Review 10.  Radiographically detectable calcium and atherosclerosis: the connection and its exploitation.

Authors:  R Detrano; S Molloi
Journal:  Int J Card Imaging       Date:  1992
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.